Granata Bio Secures $15 Million in Series A+ Funding
Granata Bio Corporation, a Boston-based biopharmaceutical firm dedicated to enhancing the global infertility medication market valued at $3.6 billion, has successfully completed a $15 million Series A+ funding round. This funding was secured exclusively from existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, along with other strategic players. To date, Granata Bio has raised over $30 million to further its mission.
Supporting Innovations in Reproductive Health
This round of funding is aimed at advancing Granata Bio’s current pipeline while exploring innovative solutions in reproductive health. The company intends to solidify its leadership in the women’s health sector and increase its portfolio of patient-centric solutions.
CEO’s Commitment to Fertility Solutions
Evan Sussman, CEO of Granata Bio, expressed his heartfelt appreciation for the ongoing support from investors, particularly citing the pivotal role of strategic partners like Gedeon Richter and CooperSurgical. Sussman emphasized Granata Bio’s dedication to improving fertility access through the development of new therapeutic options. He states, “With this new funding, we are well-positioned to accelerate the development of our current and future pipeline.”
About Granata Bio
Founded in 2018, Granata Bio is a pioneering biopharmaceutical company concentrated on women’s health and infertility solutions. The company’s extensive pipeline encompasses collaborations across several in vitro fertilization (IVF) product categories.
About Gedeon Richter
Gedeon Richter Plc. is a prominent pharmaceutical company located in Budapest, Hungary, with a growing presence in Western Europe, China, Latin America, and Australia. With a market capitalization of approximately $4.7 billion as of the end of 2023, the company recorded consolidated sales around $2.3 billion. Gedeon Richter’s product range covers crucial therapeutic areas, particularly Women’s Healthcare, and boasts one of the largest R&D units in Central Eastern Europe.
About CooperSurgical
CooperSurgical is a leading entity in fertility and women’s healthcare, focusing on empowering women and families during significant healthcare moments. The company specializes in advanced assisted reproductive technology and genomic solutions, offering over 600 medical devices that cater to women’s healthcare providers, all aimed at enhancing patient outcomes.
